Abbvie Inc. vs BioMarin Pharmaceuticals Inc
ABBV vs BMRN — side-by-side comparison from reported financials. ABBV leads 8, BMRN leads 2 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
BioMarin Pharmaceuticals Inc
BMRN · Healthcare
$54.80-0.16%Mixed
| Metric | ABBV | BMRN |
|---|---|---|
| Price | $276.43 | $54.80 |
| Market cap | $488B | $10.6B |
| Revenue (TTM) | $64.4B | $3.41B |
| Revenue growth | +1.8% | +15.4% |
| Net margin | 9.8% | 2.1% |
| Free cash flow | $18.2B | $738M |
| Net cash (debt) | ($56.2B) | — |
| 1-year price return | +19.8% | +1.8% |
| P/E | 77.4 | 145.4 |
| P/E vs own history (cheap-side %) | 23% | 45% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 1% |
| Altman Z-score | 2.33 | 1.70 |
| CV checks passed | 9 of 11 | 8 of 11 |
| Employees | 57,000 | 3,221 |
Full résumé-style profiles: ABBV CV · BMRN CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.